表紙:糖鎖解析サービスの世界市場:企業規模 (中小企業・大企業)・技術 (分光法・クロマトグラフィ・マイクロアレイ・電気泳動)・地域別
市場調査レポート
商品コード
1024366

糖鎖解析サービスの世界市場:企業規模 (中小企業・大企業)・技術 (分光法・クロマトグラフィ・マイクロアレイ・電気泳動)・地域別

Glycosylation Analysis Services Market by Company Size (Small, Mid- sized and Large), Analytical Techniques (Spectroscopy, Chromatography, Microarrays and Electrophoresis) and Key Geographical Regions

出版日: | 発行: Roots Analysis | ページ情報: 英文 342 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円
糖鎖解析サービスの世界市場:企業規模 (中小企業・大企業)・技術 (分光法・クロマトグラフィ・マイクロアレイ・電気泳動)・地域別
出版日: 2021年06月30日
発行: Roots Analysis
ページ情報: 英文 342 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗体医薬を含む遺伝子組換え糖タンパク質治療薬は、最も急速に成長している薬理活性分子のクラスの1つです。現在までにFDAで承認された生物製剤の67%以上、バイオシミラーの80%以上が何らかの形で糖化されており、同種の治療薬のパイプラインも、驚異的なペースで成長しています。

ヒトのような高等真核生物にとって、生体分子の糖鎖は、機能的な観点から重要であるだけでなく、有効性、溶解性、安定性、抗原結合に影響を与える有益な薬理学的特性を付与するものです。さらに、糖鎖は疾患の予後や診断、治療効果の予測に役立つ有望なバイオマーカーの一種です。しかし、糖鎖の分析は複雑なため、医薬品開発者や医学研究者は、必要な分析の専門知識と技術的インフラを備えた契約サービスプロバイダーへの依存度を高めています。

当レポートでは、世界の糖鎖解析サービスの市場を調査し、市場の定義と概要、参入企業と競合環境、主要サービスプロバイダーのプロファイル、サービスポートフォリオ、近年の展開、パイプラインの動向、助成金の動向、提携・協力関係の分析、M&Aの動向、潜在的クライアント、市場規模の推移・予測、企業規模・技術・地域別の内訳、専門家による見解などをまとめています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 糖鎖解析サービスプロバイダー:市場情勢

第5章 糖鎖解析サービスプロバイダー:企業の競合分析

  • 調査手法
  • 前提因子・主要パラメーター
  • 主要企業の概要

第6章 糖鎖解析サービスプロバイダー:企業プロファイル

  • 北米
    • CD BioGlyco
    • Creative Biolabs
    • Creative Proteomics
    • Thermo Fisher Scientific
  • 欧州
    • Glykos Finland
    • glyXera
    • Ludger
    • Protagen Protein Services
  • アジア太平洋・その他の地域
    • Mithra Biotechnology
    • Protein Works
    • Savyon Diagnostics
    • Syngene

第7章 表面糖鎖標的治療薬:総市場の情勢

  • パイプラインレビュー
  • 開発事業者リスト
  • ヒートマップ分析

第8章 表面糖鎖標的治療薬:学術助成金の分析

第9章 提携・協力

  • 提携モデル
  • 提携・協力リスト

第10章 M&A

  • M&Aモデル
  • M&Aリスト

第11章 潜在的クライアントに関するケーススタディ

  • Fc糖鎖改変抗体:開発者リスト
  • Fc糖鎖改変抗体治療薬:パイプラインレビュー

第12章 糖鎖解析サービス:市場規模・機会分析

  • 予測手法・前提因子
  • 市場予測:企業規模別
    • 小規模企業
    • 中規模企業
    • 大規模企業
  • 市場予測:技術別
    • 分光法
    • クロマトグラフィ
    • マイクロアレイ
    • 電気泳動
  • 市場予測:地域別
    • 米国
    • カナダ
    • 英国
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • その他の欧州地域
    • 中国
    • 日本
    • インド
    • アジア太平洋・その他の地域

第13章 専門家の見解

第14章 総論

第15章 付録:集計データ

第16章 付録:企業・組織リスト

図表

List Of Tables

  • Table 3.1 Glycan Analysis: Glycan Sample Preparation Methods
  • Table 3.2 Glycan Analysis: Glycan Separation Methods
  • Table 3.3 Glycan Analysis: Glycan Detection Methods
  • Table 4.1 Glycan Analysis Service Providers: List of Industry Players
  • Table 4.2 Glycan Analysis Service Providers (Industry Players): Information on Type of Service(s) Offered
  • Table 4.3 Glycan Analysis Service Providers (Industry Players): Information on Type of Glycoconjugate(s) and Sample(s) Analyzed
  • Table 4.4 Glycan Analysis Service Providers (Industry Players): Information on Type of Analyte(s) Processed
  • Table 4.5 Glycan Analysis Service Providers (Industry Players): Information on Type of Analytical Technique(s) Used
  • Table 4.6 Glycan Analysis Service Providers (Industry Players): Information on Application Area(s) and Additional Service(s) Offered
  • Table 4.7 Glycan Analysis Service Providers: List of Non-Industry Players
  • Table 4.8 Glycan Analysis Service Providers (Non-Industry Players): Information on Type of Analytical Technique(s) Used
  • Table 6.1 Glycan Analysis Service Providers: List of Profiled Companies
  • Table 6.2 CD BioGlyco: Company Snapshot
  • Table 6.3 CD BioGlyco: Service Portfolio
  • Table 6.4 CD BioGlyco: Recent Developments and Future Outlook
  • Table 6.5 Creative Biolabs: Company Snapshot
  • Table 6.6 Creative Biolabs: Service Portfolio
  • Table 6.7 Creative Biolabs: Recent Developments and Future Outlook
  • Table 6.8 Creative Proteomics: Company Snapshot
  • Table 6.9 Creative Proteomics: Service Portfolio
  • Table 6.10 Creative Proteomics: Recent Developments and Future Outlook
  • Table 6.11 Thermo Fisher Scientific: Company Snapshot
  • Table 6.12 Thermo Fisher Scientific: Service Portfolio
  • Table 6.13 Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 6.14 Glykos Finland: Company Snapshot
  • Table 6.15 Glykos Finland: Service Portfolio
  • Table 6.16 Glykos Finland: Recent Developments and Future Outlook
  • Table 6.17 glyXera: Company Snapshot
  • Table 6.18 glyXera: Service Portfolio
  • Table 6.19 glyXera: Recent Developments and Future Outlook
  • Table 6.20 Ludger: Company Snapshot
  • Table 6.21 Ludger: Service Portfolio
  • Table 6.22 Ludger: Recent Developments and Future Outlook
  • Table 6.23 Protagen Protein Services: Company Snapshot
  • Table 6.24 Protagen Protein Services: Service Portfolio
  • Table 6.25 Protagen Protein Services: Recent Developments and Future Outlook
  • Table 6.26 Mithra Biotechnology: Company Snapshot
  • Table 6.27 Mithra Biotechnology: Service Portfolio
  • Table 6.28 Mithra Biotechnology: Recent Developments and Future Outlook
  • Table 6.29 Protein Works: Company Snapshot
  • Table 6.30 Protein Works: Service Portfolio
  • Table 6.31 Protein Works: Recent Developments and Future Outlook
  • Table 6.32 Savyon Diagnostics: Company Snapshot
  • Table 6.33 Savyon Diagnostics: Service Portfolio
  • Table 6.34 Savyon Diagnostics: Recent Developments and Future Outlook
  • Table 6.35 Syngene: Company Snapshot
  • Table 6.36 Syngene: Service Portfolio
  • Table 6.37 Syngene: Recent Developments and Future Outlook
  • Table 7.1 Surface Glycan Targeting Therapeutics: Information on Phase of Development, Target Disease Indication and Type of Drug Molecule
  • Table 7.2 Surface Glycan Targeting Therapeutics: Information on Target Glycan / Glycoconjugate Molecule, Type of Therapy and Technology Platforms
  • Table 7.3 Surface Glycan Targeting Therapeutics: List of Developers
  • Table 9.1 List of Partnerships and Collaborations, 2015-2021 (till March)
  • Table 10.1 List of Mergers and Acquisitions, 2015-2021 (till March)
  • Table 11.1 Fc Glycoengineered Antibodies: List of Developers
  • Table 11.2 Fc Glycoengineered Antibodies: List of Drugs
  • Table 13.1 GlycoAnalytics Core, University of California: Key Highlights
  • Table 15.1 Glycan Analysis Service Providers: Overall Market Landscape
  • Table 15.2 Glycan Analysis Service Providers (Industry Players): Distribution by Year of Establishment
  • Table 15.3 Glycan Analysis Service Providers (Industry Players): Distribution by Company Size
  • Table 15.4 Glycan Analysis Service Providers (Industry Players): Distribution by Location of Headquarters
  • Table 15.5 World Map Representation: Distribution by Geography
  • Table 15.6 Glycan Analysis Service Providers (Industry Players): Distribution by Availability of Contract Development and Manufacturing Capabilities
  • Table 15.7 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Service(s) Offered
  • Table 15.8 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Glycoconjugate(s) and Glycan(s) Analyzed
  • Table 15.9 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Sample(s) Analyzed
  • Table 15.10 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Analyte(s) Processed
  • Table 15.11 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Analytical Technique(s) Used
  • Table 15.12 Glycan Analysis Service Providers (Industry Players): Distribution by Application Area(s)
  • Table 15.13 Glycan Analysis Service Providers (Industry Players): Distribution by Additional Service(s) Offered
  • Table 15.14 Glycan Analysis Service Providers (Industry Players): Distribution by Additional Product(s) Offered
  • Table 15.15 Glycan Analysis Service Providers (Non-Industry Players): Distribution by Service Location
  • Table 15.16 Glycan Analysis Service Providers (Non-Industry Players): Distribution by Type of Service(s) Offered
  • Table 15.17 Glycan Analysis Service Providers (Non-Industry Players): Distribution by Type of Analytical Technique(s) Used
  • Table 15.18 Thermo Fisher Scientific: Annual Revenues, FY 2016-Q1 2021 (USD Billion)
  • Table 15.19 Syngene: Annual Revenues, FY 2016-FY 2021 (INR Million)
  • Table 15.20 Surface Glycan Targeting Therapeutics: Distribution by Phase of Development
  • Table 15.21 Surface Glycan Targeting Therapeutics: Distribution by Target Disease Indication and Therapeutic Area
  • Table 15.22 Surface Glycan Targeting Therapeutics: Distribution by Type of Drug Molecule
  • Table 15.23 Surface Glycan Targeting Therapeutics: Distribution by Phase of Development and Therapeutic Area
  • Table 15.24 Surface Glycan Targeting Therapeutics: Distribution by Type of Drug Molecule and Therapeutic Area
  • Table 15.25 Surface Glycan Targeting Therapeutics: Distribution by Target Glycan / Glycoconjugate Molecule
  • Table 15.26 Surface Glycan Targeting Therapeutics: Distribution by Type of Therapy
  • Table 15.27 Popular Technology Platforms: Distribution by Number of Products
  • Table 15.28 Surface Glycan Targeting Therapy Developers: Distribution by Type of Player
  • Table 15.29 Surface Glycan Targeting Therapy Developers: Distribution by Year of Establishment
  • Table 15.30 Surface Glycan Targeting Therapy Developers: Distribution by Company Size
  • Table 15.31 Surface Glycan Targeting Therapy Developers: Distribution by Location of Headquarters
  • Table 15.32 World Map Representation: Analysis by Geography
  • Table 15.33 Leading Developers: Distribution by Number of Products
  • Table 15.34 Heat Map Analysis: Distribution by Company Size, Location of Headquarters and Products' Stage of Development
  • Table 15.35 Grant Analysis: Cumulative Trend by Year of Grant Award, 2016-2021 (till March)
  • Table 15.36 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), 2016-2021 (till March)
  • Table 15.37 Grant Analysis: Distribution by Administering Institute Center
  • Table 15.38 Grant Analysis: Distribution by Support Period
  • Table 15.39 Grant Analysis: Distribution by Funding Institute Center and Support Period
  • Table 15.40 Grant Analysis: Distribution by Type of Grant Application
  • Table 15.41 Grant Analysis: Distribution by Purpose of Grant Award
  • Table 15.42 Grant Analysis: Distribution by Activity Code
  • Table 15.43 Grant Analysis: Distribution by Study Section Involved
  • Table 15.44 Popular NIH Departments: Distribution by Number of Grants
  • Table 15.45 Grant Analysis: Distribution by Types of Recipient Organizations
  • Table 15.46 Most Prominent Program Officers: Distribution by Number of Grants
  • Table 15.47 Popular Recipient Organization: Distribution by Number of Grants
  • Table 15.48 Grant Analysis: Regional Distribution of Recipient Organizations
  • Table 15.49 Partnerships and Collaborations: Cumulative Trend by Year of Partnership, 2015-2021 (till March)
  • Table 15.50 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 15.51 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2021 (till March)
  • Table 15.52 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Table 15.53 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 15.54 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Parent Company
  • Table 15.55 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Parent Company
  • Table 15.56 Most Active Players: Distribution by Number of Partnerships
  • Table 15.57 Partnerships and Collaborations: Regional Distribution
  • Table 15.58 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 15.59 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 15.60 Mergers and Acquisitions: Distribution by Type of Deal
  • Table 15.61 Mergers and Acquisitions: Cumulative Year-Wise Distribution, 2015-2021 (till March)
  • Table 15.62 Mergers and Acquisitions: Distribution by Geography
  • Table 15.63 Mergers and Acquisitions: Intercontinental and Intracontinental Distribution
  • Table 15.64 Acquisitions: Distribution by Company Size
  • Table 15.65 Acquisitions: Ownership Change Matrix
  • Table 15.66 Mergers and Acquisitions: Key Players
  • Table 15.67 Mergers and Acquisitions: Key Value Drivers
  • Table 15.68 Fc Glycoengineered Antibody Product Developers: Distribution by Year of Establishment
  • Table 15.69 Fc Glycoengineered Antibody Product Developers: Distribution by Company Size
  • Table 15.70 Fc Glycoengineered Antibody Product Developers: Distribution by Location of Headquarters
  • Table 15.71 Leading Players: Distribution by Number of Products
  • Table 15.72 Fc Glycoengineered Antibodies: Distribution by Phase of Development
  • Table 15.73 Fc Glycoengineered Antibodies: Distribution by Target Disease Indication
  • Table 15.74 Fc Glycoengineered Antibodies: Distribution by Therapeutic Area
  • Table 15.75 Fc Glycoengineered Antibodies: Distribution by Type of Antibody
  • Table 15.76 Fc Glycoengineered Antibodies: Distribution by Biological Target
  • Table 15.77 Fc Glycoengineered Antibodies: Distribution by Type of Therapy
  • Table 15.78 Fc Glycoengineered Antibodies: Distribution by Route of Administration
  • Table 15.79 Fc Glycoengineered Antibodies: Distribution by Impact of Fc Engineering
  • Table 15.80 Fc Glycoengineered Antibodies: Distribution by Technology Platform Used
  • Table 15.81 Global Glycan Analysis Services Market, 2021-2030 (USD Million)
  • Table 15.82 Global Glycan Analysis Services Market: Distribution by Company Size, 2021 and 2030: Base Scenario (USD Million)
  • Table 15.83 Glycan Analysis Services Market for Small Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.84 Glycan Analysis Services Market for Mid-sized Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.85 Glycan Analysis Services Market for Large Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.86 Global Glycan Analysis Services Market: Distribution by Type of Analytical Technique (USD Million), 2021 and 2030
  • Table 15.87 Glycan Analysis Services Market for Spectroscopy-based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.88 Glycan Analysis Services Market for Chromatography-based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.89 Glycan Analysis Services Market for Microarray- based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.90 Glycan Analysis Market for Electrophoresis- based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.91 Global Glycan Analysis Services Market: Distribution by Geography (USD Million), 2021 and 2030
  • Table 15.92 Glycan Analysis Services Market in the US, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.93 Glycan Analysis Services Market in Canada, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.94 Glycan Analysis Services Market in the UK, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.95 Glycan Analysis Services Market in France, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.96 Glycan Analysis Services Market in the Germany, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.97 Glycan Analysis Services Market in Spain, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.98 Glycan Analysis Services Market in Italy, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.99 Glycan Analysis Services Market in Rest of Europe, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.100 Glycan Analysis Services Market in China, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.101 Glycan Analysis Services Market in Japan, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.102 Glycan Analysis Services Market in India, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.103 Glycan Analysis Services Market in Other Asian Countries and Rest of the World, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)

List of Companies

The following companies and organizations are mentioned in the report.

  • 1. 10x Genomics
  • 2. A*STAR Bioprocessing Technology Institute (BTI)
  • 3. Abzena
  • 4. Academia Sinica
  • 5. AddLife
  • 6. Admescope (Acquired by Symerers)
  • 7. Advantar Laboratories (Acquired by Eurofins Scientific)
  • 8. AGC Biologics
  • 9. Agency for Science, Technology and Research (A*STAR)
  • 10. Agilent Technologies
  • 11. Airway Therapeutics
  • 12. Ajinomoto Althea
  • 13. Ajinomoto Bio-Pharma Services
  • 14. Alcami
  • 15. Allergan Biologics
  • 16. Alliance Protein Laboratories (Acquired by KBI Biopharma)
  • 17. Almac
  • 18. Alphalyse
  • 19. Alvotech
  • 20. Amgen
  • 21. ams Laboratories (Acquired by Eurofins Scientific)
  • 22. Amthera
  • 23. Analytical Instrumentation Core, Boston University School of Medicine
  • 24. Ansun Biopharma (formerly NexBio)
  • 25. Applied Process Company (APC)
  • 26. Applied Pharmaceutical Innovation (API)
  • 27. Aragen Bioscience
  • 28. Argenx
  • 29. Asparia Glycomics
  • 30. AstraZeneca
  • 31. Australian Proteome Analysis Facility (APAF), Macquarie University
  • 32. Avid Bioservices (formerly Peregrine Pharmaceuticals)
  • 33. Avomeen (Acquired by Element Materials Technology)
  • 34. Baylor College of Medicine
  • 35. Be The Match BioTherapies
  • 36. Beroni Group
  • 37. BioAnalytix (Acquired by Protagen Protein Services)
  • 38. Biofidus
  • 39. Biogen
  • 40. Biomedica (Acquired by AddLife)
  • 41. Biomedical FT-ICR Mass Spectrometry Laboratory, University of Alabama at Birmingham
  • 42. Biomeva (Acquired by AGC)
  • 43. BioMS
  • 44. BioNTech
  • 45. BioPharmaSpec
  • 46. BioReliance
  • 47. BiosanaPharma
  • 48. Bio-Shape
  • 49. Biosilu Healthcare
  • 50. Boehringer Ingelheim
  • 51. BRI Biopharmaceutical Research (Acquired by Frontage Laboratories)
  • 52. Cambridge Biologics
  • 53. Canadian Glycomics Network (GlycoNet)
  • 54. Cantargia
  • 55. CD BioGlyco
  • 56. CD Genomics
  • 57. Cell Signaling Technology (CST)
  • 58. CellmAbs
  • 59. Celonic
  • 60. Centre for Cellular and Molecular Platforms (C-CAMP)
  • 61. Centre for Process Innovation (CPI)
  • 62. Centre for the AIDS Programme of Research in South Africa (CAPRISA)
  • 63. Charles River Laboratories
  • 64. Chembind
  • 65. Chemily Glycoscience
  • 66. Chemistry Research Laboratory, University of Oxford
  • 67. China Biotech Services (formerly Rui Kang Pharmaceutical Group Investments)
  • 68. CHO Pharma
  • 69. Chromous Biotech
  • 70. CMC Biologics (Acquired by AGC)
  • 71. Cobra Biologics (Acquired by Cognate BioServices)
  • 72. Cognate BioServices (Acquired by Charles River Laboratories)
  • 73. Complex Carbohydrate Research Center (CCRC), University of Georgia
  • 74. Cornerstone Analytical Laboratories (CAL)
  • 75. Consortium de recherche biopharmaceutique (CQDM)
  • 76. Creative Biolabs
  • 77. Creative Proteomics
  • 78. Croatian Agency for SMEs, Innovations and Investments (HAMAG-BICRO)
  • 79. Current Medical Information Center (CMIC)
  • 80. Cytiva (formerly GE Healthcare Life Sciences)
  • 81. Cytovance Biologics (Acquired by Hepalink USA)
  • 82. Daiichi Sankyo
  • 83. Danaher
  • 84. DCPrime
  • 85. Delenex Therapeutics (Acquired by Kuur Therapeutics)
  • 86. Department of Biology, University of York
  • 87. Development Center for Biotechnology (DCB)
  • 88. Dextra Laboratories
  • 89. Diteba
  • 90. DNA Xperts
  • 91. EirGenix
  • 92. Element Materials Technology
  • 93. Elicityl
  • 94. Elion Labs (Acquired by KBI Biopharma)
  • 95. Elpiscience
  • 96. Emory Comprehensive Glycomics Core (ECGC), Emory University School of Medicine
  • 97. Eurofins BioPharma Product Testing
  • 98. Eurofins DiscoverX
  • 99. Eurofins Scientific
  • 100. Ferrier Research Institute, Victoria University of Wellington
  • 101. ForteBio Pall Life Science
  • 102. Frontage Laboratories
  • 103. Functional Genomics Center Zurich
  • 104. Gemini Biosciences
  • 105. Genentech
  • 106. Genos Glyco
  • 107. Genovis
  • 108. GenScript ProBio
  • 109. GeoVax
  • 110. Gilead Sciences
  • 111. GlaxoSmithKline
  • 112. Glycan Therapeutics
  • 113. GLYcoDiag
  • 114. GlycoDisplay
  • 115. GlycoEra
  • 116. Glycomics Core, Beth Israel Deaconess Medical Center (BIDMC)
  • 117. GlycoMScan
  • 118. GlycoNex
  • 119. Glycosciences Laboratory, Imperial College London
  • 120. GlycoScreen
  • 121. GlycoSeLect
  • 122. GlycoTechnica
  • 123. GlycoThera (Acquired by Alvotech)
  • 124. Glycotope
  • 125. Glycovax Pharma
  • 126. Glyde Bio
  • 127. GlykoGen
  • 128. Glykos Finland
  • 129. GlyTR Therapeutics
  • 130. glyXera
  • 131. GO Therapeutics
  • 132. Goodwin Biotechnology
  • 133. GP BioSciences
  • 134. Helmholtz-Zentrum Dresden-Rossendorf (HZDR)
  • 135. Helsinki Institute of Life Science (HiLIFE)
  • 136. Hepalink USA (subsidiary of Shenzhen Hepalink Pharmaceutical)
  • 137. HJB
  • 138. Horizon Therapeutics
  • 139. Humanigen
  • 140. Icahn School of Medicine at Mount Sinai
  • 141. InnoMol
  • 142. Innovation Network Corporation of Japan (INCJ)
  • 143. Institute for Glycomics, Griffith University
  • 144. Institute of Chemistry, Slovak Academy of Sciences
  • 145. International AIDS Vaccine Initiative (IAVI)
  • 146. Intertek
  • 147. Iovance Biotherapeutics
  • 148. JSR Life Sciences
  • 149. KBI Biopharma (Acquired by JSR)
  • 150. King's College London
  • 151. Kuur Therapeutics (formerly Cell Medica)
  • 152. Kymos Pharma Services
  • 153. Kyowa Hakko Kirin
  • 154. LakePharma
  • 155. Lebrilla League
  • 156. Leo Pharma
  • 157. Livogen Pharmed
  • 158. Ludger
  • 159. MabSpace Biosciences (Acquired by HJB)
  • 160. MabVax Therapeutics (Acquired by BioNTech)
  • 161. Madison Dearborn Partners (MDP)
  • 162. Max Planck Institute of Colloids and Interfaces (MPICI)
  • 163. McMaster University
  • 164. Medicinal Chemistry Pharmaceutical
  • 165. Menarini
  • 166. Meridian Biopharmaceuticals
  • 167. Mithra Biotechnology
  • 168. MOBILion Systems
  • 169. Monash Proteomics & Metabolomics Facility (MPMF), Monash University
  • 170. MS Bioworks
  • 171. MtoZ Biolabs
  • 172. National Cancer Institute
  • 173. National Centre for Biological Sciences (NCBS), Tata Institute of Fundamental Research
  • 174. National Heart, Lung, and Blood Institute
  • 175. National Institute for Bioprocessing Research & Training (NIBRT)
  • 176. National Institute of Allergy and Infectious Diseases (NIAID)
  • 177. New England Biolabs (NEB)
  • 178. Nitto Avecia Pharma Services
  • 179. Northwestern University
  • 180. Novatia
  • 181. OBI Pharma
  • 182. Octapharma
  • 183. OmniChem (Acquired by Ajinomoto Althea)
  • 184. OncoCare Therapeutics
  • 185. Oncora Medical
  • 186. OncoVent
  • 187. ONK Therapeutics
  • 188. Oragenics
  • 189. Otsuka Pharmaceutical
  • 190. Pace Analytical Life Sciences
  • 191. Pacific BioLabs
  • 192. PAIA Biotech
  • 193. Palleon Pharmaceuticals
  • 194. Paradigm Biopharmaceuticals
  • 195. Paraná's Institute of Technology (TECPAR)
  • 196. Pfizer
  • 197. Pharmaprogress (Acquired by KYMOS)
  • 198. PhAST (Acquired by Eurofins BioPharma Product Testing)
  • 199. Pneumagen
  • 200. Poochon Scientific
  • 201. Portuguese Oncology Institute of Porto (IPO Porto)
  • 202. Profacgen
  • 203. ProGlycAn, University of Natural Resources and Life Sciences Vienna (BOKU)
  • 204. Prolytic (Acquired by KYMOS)
  • 205. Protagen Protein Services
  • 206. Protein Works
  • 207. Proteodynamics
  • 208. ProteomeTech
  • 209. Proteomics Core Facility (PCF), University of Gothenberg
  • 210. Proteomics International
  • 211. ProtTech
  • 212. ProZyme (Acquired by Agilent Technologies)
  • 213. Quality Assistance
  • 214. Quantum Hi-Tech (China) Biological (Acquired by Shanghai ChemPartner)
  • 215. Quest PharmaTech
  • 216. Reading Scientific Services
  • 217. Realist Pharma
  • 218. Recepta Biopharma
  • 219. Recombio
  • 220. Research Triangle Institute (RTI)
  • 221. RMI Laboratories (Acquired by Frontage Laboratories)
  • 222. Roche
  • 223. Rockefeller University
  • 224. Samsung BioLogics
  • 225. Sandor LifeSciences
  • 226. Sanofi
  • 227. Sartorius Stedim Biotech
  • 228. Savyon Diagnostics
  • 229. Scancell
  • 230. School of Biological and Chemical Sciences, Queen Mary University of London
  • 231. SCIEX
  • 232. Scripps Research
  • 233. Seagen
  • 234. SGS
  • 235. Shanghai Applied Protein Technology
  • 236. Shanghai ChemPartner
  • 237. Shantani Proteome Analytics
  • 238. Siamab Therapeutics
  • 239. Sienna Cancer Diagnostics (Acquired by Bard1 Life Sciences)
  • 240. Sinensis Life Sciences (Acquired by Eurofins Scientific)
  • 241. Sinobioway Cell Therapy
  • 242. SMAanalytical
  • 243. Solvias
  • 244. Spectralys Biotech
  • 245. Spectrometry Cores, The Regents of the University of California
  • 246. STC Biologics
  • 247. Sumitomo Bakelite
  • 248. Sussex Research
  • 249. Symeres (formerly MercachemSyncom)
  • 250. Syngene
  • 251. Tacalyx
  • 252. tebu-bio
  • 253. Tentamus
  • 254. TG Therapeutics
  • 255. TheraProteins
  • 256. Thermo Fisher Scientific
  • 257. Tmunity Therapeutics
  • 258. Tubulis
  • 259. GlycoAnalytics Core, University of California
  • 260. United BioPharma
  • 261. United Therapeutics
  • 262. University of Adelaide
  • 263. University of Arkansas
  • 264. University of California
  • 265. University of Florida
  • 266. University of Georgia
  • 267. University of Nottingham
  • 268. University of Pittsburgh
  • 269. Proteomics Core, UT Southwestern Medical Center
  • 270. VelaLabs (Acquired by Tentamus)
  • 271. ViaMune
  • 272. VIMTA
  • 273. Vir Biotechnology
  • 274. Visterra (formerly Parasol Therapeutics)
  • 275. VProteomics
  • 276. VxP Biologics
  • 277. Washington University
  • 278. Waters
  • 279. Weill Cornell Medicine
  • 280. Wolfe Laboratories (Acquired by Pace Analytical Life Sciences)
  • 281. WuXi Biologics
  • 282. Z Biotech
  • 283. Zelle Biotechnology
目次

Title:
Glycosylation Analysis Services Market
by Company Size (Small, Mid- sized and Large), Analytical Techniques (Spectroscopy, Chromatography, Microarrays and Electrophoresis) and Key Geographical Regions (North America (US, Canada), Europe (Italy, Spain, Germany, France, UK) and Asia- Pacific (India, Japan, China)): Industry Trends and Global Forecasts, 2021-2030.

Overview:

Recombinant glycoprotein therapeutics, which include antibody-based interventions, have emerged as one of the fastest growing classes of pharmacologically active molecules. Till date, over 67% of biologics and 80% of biosimilars approved by the FDA, feature some form of glycosylation. In fact, the pipeline of such interventions is also growing at a commendable pace (CAGR of over 20%). It is important to highlight that for higher eukaryotes, such as humans, glycosylation of certain biomolecules is not only important from the functional perspective, but it also imparts beneficial pharmacological properties, which influence efficacy, solubility, stability, and antigen binding. Further, glycans represent a promising class of biomarkers that are useful for disease prognosis, diagnosis, and assist in the prediction of treatment efficacy. In this context, several tumor-associated (aberrant) glycan molecules (such as Tn, sialyl-T and sialyl-Tn), as well as virulent glycoproteins on pathogenic viral envelopes (such as the glycan shield associated with the SARS-CoV-2 spike glycoprotein), are presently being investigated as viable therapeutic targets.

Given the complexities associated with glycan analysis, it is difficult for non-specialist researchers and therapy developers, to effectively analyze this aspect of biomolecules. Moreover, the associated analytical procedures are further complicated by multi-step analytical protocols and technically demanding expertise, which eventually lead to contamination of samples and lack of reproducibility in test results. Recent evolution in the approach (such as the use of orthogonal techniques and the middle-up strategy) to analyzing data generated from the diverse bioanalytical techniques used in glycan profiling, necessitate extensive domain expertise. Consequently, drug developers and medical researchers are increasingly relying on contract service providers with the necessary analytical expertise and technical infrastructure, for their glycan analysis needs. Currently, more than 130 industry and non- industry players claim to be actively providing glycan analysis services. In the recent past, a number of stakeholders in the services sector, have forged strategic alliances with and / or acquired other players offering glycan analysis or related services, in order to further enhance their respective portfolios. Considering the growing trend of outsourcing and the ongoing efforts of service providers to improve / expand their respective offerings, we believe the contract services market for glycan analysis is likely to grow at a steady pace, till 2030.

Scope of the Report:

The "Glycosylation Analysis Services Market, 2021- 2030" report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the market, over the next decade. The study underlines an in-depth analysis of the various services offered for assessing glycosylation related attributes, in biopharmaceutical, biomedical and clinical samples. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the glycan analysis services market, highlighting the contributions of industry players, along with the information on their year of establishment, company size, geographical location of headquarters, type of service(s) offered (glycan profiling and heterogeneity analysis, glycosylation site mapping and occupancy analysis, site- specific glycosylation analysis, glycan structure analysis, monosaccharide quantification analysis and protein- glycan binding analysis), type of glycoconjugate and glycan analyzed (N- glycan, O- glycan and glycolipid), type of sample analyzed (biotherapeutics and cellular), type of analyte processed (intact glycoprotein, glycopeptide, released glycan, monosaccharide and polysaccharide), type of analytical technique used (chromatography, spectroscopy, electrophoresis and microarray- based technique), application area (R&D / early- stage drug development and in- process drug development) It also provides information on the additional services offered (peptide mapping, post- translational modification analysis, protein terminal sequencing and glycan / glycoconjugate synthesis), and availability of synthetic glycans and analytical kits / tests. In addition, it provides information on the type of glycoanalytical service offered and type of technique used by non-industry players.
  • A region-wise company competitiveness analysis, highlighting the most prominent glycan analysis service providers, based on their supplier strength (in terms of experience and company size), and portfolio specifications (in terms of number of services offered, number of analytical techniques used, types of glycans analyzed, types of analytes processed and applications).
  • Elaborate profiles of prominent service providers in this domain. Each company profile includes a brief overview of the company, its financial information (if available), information on service portfolio, recent developments, and an informed future outlook.
  • A detailed assessment of the current market landscape of surface glycan targeting therapeutics, providing information on the phase of development (commercial, clinical, preclinical, and discovery) of lead candidates, target disease indication and therapeutic area, type of drug molecule (antibody, antibody-drug conjugate, enzyme, glyco- conjugate vaccine and CAR- T cells), target glycan / glycoconjugate molecule, type of therapy (monotherapy, combination therapy and both), and technology platform used. In addition, it provides details on drug developer(s), including information on their year of establishment, company size, and location of headquarters.
  • A detailed analysis of grants that have been awarded to research institutes for surface glycan targeting therapeutic projects, during the period, 2016 and 2021, based on several relevant parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, type of recipient organizations and focus area. In addition, it highlights geographical distribution of recipient organizations, popular funding institute centers, prominent program officers, and popular recipient organizations.
  • An analysis of the partnerships that have been established in this domain since 2015, covering instances of acquisitions and mergers, licensing agreements, product development agreements, process development agreement, research agreements, and other relevant types of deals.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired during the time period between 2015- 2021, based on several relevant parameters, such as year of agreement, type of deal, geographical location of headquarters, company size, and the key value drivers. In addition, it represents an ownership change matrix, providing a summary of the involvement of private and public sector entities in this domain.
  • A case study on the potential clients of glycan analysis services providers; it presents a list of Fc glycoengineered antibody developers, along with information on their year of establishment, company size, and location of headquarters. In addition, it provides information on phase of development of the glycoengineered antibody, target disease indication, therapeutic area, type of molecule, its biological target, type of therapy, route of administration, impact of Fc engineering and technology platform used.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities of glycan analysis service providers. Based on various parameters, such as the number of projects completed annually, price of the projects, the overall R&D expenditure available to CROs and the overall growth of the glycoprotein therapeutics market, we have developed informed estimates on the evolution of the market for the period 2021-2030. Our year-wise projections of the current and forecasted opportunity have further been segmented across company size (small, mid-sized and large), analytical techniques used (spectroscopy, chromatography, microarrays and electrophoresis), key geographical locations (North America, Europe and Asia- Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Biswa Choudhury (Technical Director, GlycoAnalytics Core, University of California)
  • Erdmann Rapp (Founder and Chief Executive Officer, glyXera)
  • Juhani Saarinen (Chief Executive Officer, Glykos Finland)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading industry and non- industry players offering glycan analysis services?
  • Which are the key geographies where glycan analysis service providers are located?
  • What are the common analytical techniques used by the service providers?
  • What are the prevalent R&D trends related to surface glycan targeting therapies?
  • Which surface glycan molecules are targeted by such therapies?
  • What are the key therapeutic areas for which such therapies are being / have been developed?
  • Who are the leading players engaged in the development of surface glycan targeting therapies?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • What are the key value drivers of the merger and acquisition activity within this domain?
  • How is the current and future opportunity, related to glycan analysis services, likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It offers a high- level view on the likely evolution of the glycan analysis services market in the mid to long term.

Chapter 3 provides a general introduction to glycans and glycoconjugates, laying emphasis on the importance of glycosylation analysis in biopharmaceutical development and biomarker discovery. The chapter describes the methodologies used to analyze intact and released glycans, and the various reagents and analytical techniques that form the basis for such tests. In addition, the chapter highlights the key considerations for selecting a glycan analysis service provider, along with the benefits and risks associated with outsourcing glyco- analytical operations.

Chapter 4 provides an overview of the overall glycan analysis services landscape, including information related to over 130 industry and non-industry players offering contract services for glycan analysis. It features an in- depth analysis of the industry players, based on a number of parameters, such as year of establishment, company size, geographical location of headquarters, type of service(s) offered (glycan profiling and heterogeneity analysis, glycosylation site mapping and occupancy analysis, site- specific glycosylation analysis, glycan structure analysis, monosaccharide quantification analysis and protein- glycan binding analysis), type of glycoconjugate and glycan analyzed (N- glycan, O- glycan and glycolipid), type of sample analyzed (biotherapeutics and cellular), type of analyte processed (intact glycoprotein, glycopeptide, released glycan, monosaccharide and polysaccharide), type of analytical technique used (chromatography, spectroscopy, electrophoresis and microarray- based technique),application area (R&D / early- stage drug development and in- process drug development). The chapter also provides information on additional service(s) offered (peptide mapping, post- translational modification analysis, protein terminal sequencing and glycan / glycoconjugate synthesis), and availability of synthetic glycans and analytical kits / tests. In addition, it includes an analysis of non- industry players based on the type of glycoanalytical service offered and analytical technique used by them.

Chapter 5 provides an insightful competitiveness analysis of the glycan analysis service providers based in North America, Europe and Asia-Pacific. The analysis compares the capabilities of companies on the basis of supplier strength (based on the year of establishment and size of the service provider) and service portfolio strength (in terms of number of services offered, number of analytical techniques used, types of glycans analyzed, types of analytes processed and number of applications).

Chapter 6 includes detailed profiles the key players that are active in this domain. Each company profile features a brief overview of the company, financial information (if available), information on service portfolio, recent developments and an informed future outlook.

Chapter 7 provides information on more than 80 development programs for surface glycan targeting therapeutics that are either approved or being developed across various phase of development (commercial, clinical, preclinical, and discovery) of lead candidates, target disease indication and therapeutic area, type of drug molecule (antibody, antibody- drug conjugate, enzyme, glyco- conjugate vaccine and CAR- T cells), target glycan / glycoconjugate molecule, type of therapy (monotherapy, combination therapy and both), and technology platform used. In addition, it provides details on drug developer(s), including information on their year of establishment, company size, and location of their headquarters.

Chapter 8 provides an analysis of the grants awarded to research institutes for the projects related to surface glycan therapeutics, during the period 2016 and 2021, based on several important parameters, such year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, focus area, study section involved, and type of recipient organizations. In addition, it highlights popular funding institute centers, prominent program officers, and popular recipient organizations.

Chapter 9 features a discussion on the collaborations and partnerships that have been established in this domain since 2015. It includes a brief description of various types of partnership models (acquisitions and mergers, licensing agreements, product development agreements, process development agreements, research agreements, and other agreements) that have been adopted by stakeholders in this domain. In addition, it includes a detailed analysis of partnerships, based on year of partnership, type of partnership, and regional activity.

Chapter 10 presents insights from a detailed analysis of the mergers and acquisitions that have taken place in this domain, during the period 2015- 2021. It is worth mentioning that the data captured during our research was analyzed based on multiple parameters, such as year of agreement, type of deal, geographical location, size and ownership of the companies involved, and the key value drivers.

Chapter 11 presents a case study on the potential clients of glycan analysis services providers, featuring a list of Fc glycoengineered antibody developers, along with information on their year of establishment, company size, and location of headquarters. In addition, it provides information on phase of development of the glycoengineered antibody, target disease indication, therapeutic area, type of molecule, its biological target, type of therapy, route of administration, impact of Fc engineering and technology platform used.

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of glycan analysis services market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented across company size (small, mid- sized and large), analytical techniques used (spectroscopy, chromatography, microarrays and electrophoresis) and key geographical locations (North America, Europe and Asia- Pacific).

Chapter 13 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Biswa Choudhury (Technical Director, GlycoAnalytics Core, University of California), Erdmann Rapp (Chief Executive Officer, glyXera) and Juhani Saarinen (Founder and Chief Executive Officer, Glykos Finland).

Chapter 14 is a summary of the overall report. It presents a list of key takeaways and our independent opinions on the current market scenario.

Chapter 15 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 16 is an appendix that provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

  • 2.1. Chapter Overview

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Glycans and Glycoconjugates
  • 3.3. Glycosylation of Therapeutic Proteins
  • 3.4. Overview of Protein Glycosylation Analysis (Glycan Analysis)
    • 3.4.1. Methods Used in Glycan Analysis
    • 3.4.2. Techniques Used for Glycan Analysis
  • 3.5. Outsourcing Glycan Analysis
    • 3.5.1. Need for Outsourcing
    • 3.5.2. Advantages of Outsourcing
    • 3.5.3. Guidelines for Selecting a Service Provider
  • 3.6. Concluding Remarks

4. GLYCAN ANALYSIS SERVICE PROVIDERS: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Glycan Analysis Service Providers: Overall Market Landscape
    • 4.2.1. Glycan Analysis Service Providers: Industry Players
      • 4.2.1.1. Analysis by Year of Establishment
      • 4.2.1.2. Analysis by Company Size
      • 4.2.1.3. Analysis by Location of Headquarters
      • 4.2.1.4. Analysis by Availability of Contract Development and Manufacturing Capabilities
      • 4.2.1.5. Analysis by Type of Service Offered
      • 4.2.1.6. Analysis by Type of Glycoconjugate / Glycan Analyzed
      • 4.2.1.7. Analysis by Type of Sample Processed
      • 4.2.1.8. Analysis by Type of Analyte Processed
      • 4.2.1.9. Analysis by Type of Analytical Technique Used
      • 4.2.1.10. Analysis by Application Area
      • 4.2.1.11. Analysis by Additional Services Offered
      • 4.2.1.12. Analysis by Additional Products Offered
    • 4.2.2. Glycan Analysis Service Providers: Non-Industry Players
      • 4.2.2.1. Analysis by Service Location
      • 4.2.2.2. Analysis by Type of Service Offered
      • 4.2.2.3. Analysis by Type of Analytical Technique Used

5. GLYCAN ANALYSIS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Methodology
  • 5.3. Assumptions / Key Parameters
    • 5.3.1. Competitiveness Analysis: Glycan Analysis Service Providers in North America
    • 5.3.2. Competitiveness Analysis: Glycan Analysis Service Providers in Europe
    • 5.3.3. Competitiveness Analysis: Glycan Analysis Service Providers in Asia-Pacific and rest of the world
  • 5.4. Summary of Key Players

6. GLYCAN ANALYSIS SERVICE PROVIDERS: COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Glycan Analysis Service Providers: North America
    • 6.2.1. CD BioGlyco
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Service Portfolio
      • 6.2.1.3. Recent Developments and Future Outlook
    • 6.2.2. Creative Biolabs
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Service Portfolio
      • 6.2.2.3. Recent Developments and Future Outlook
    • 6.2.3. Creative Proteomics
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Service Portfolio
      • 6.2.3.3. Recent Developments and Future Outlook
    • 6.2.4. Thermo Fisher Scientific
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Financial Information
      • 6.2.4.3. Service Portfolio
      • 6.2.4.4. Recent Developments and Future Outlook
  • 6.3. Glycan Analysis Service Providers: Europe
    • 6.3.1. Glykos Finland
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Service Portfolio
      • 6.3.1.3. Recent Developments and Future Outlook
    • 6.3.2. glyXera
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Service Portfolio
      • 6.3.2.3. Recent Developments and Future Outlook
    • 6.3.3. Ludger
      • 6.3.3.1. Company Overview
      • 6.3.3.2. Service Portfolio
      • 6.3.3.3. Recent Developments and Future Outlook
    • 6.3.4. Protagen Protein Services
      • 6.3.4.1. Company Overview
      • 6.3.4.2. Service Portfolio
      • 6.3.4.3. Recent Developments and Future Outlook
  • 6.4. Glycan Analysis Service Providers: Asia-Pacific and rest of the world
    • 6.4.1. Mithra Biotechnology
      • 6.4.1.1. Company Overview
      • 6.4.1.2. Service Portfolio
      • 6.4.1.3. Recent Developments and Future Outlook
    • 6.4.2. Protein Works
      • 6.4.2.1. Company Overview
      • 6.4.2.2. Service Portfolio
      • 6.4.2.3. Recent Developments and Future Outlook
    • 6.4.3. Savyon Diagnostics
      • 6.4.3.1. Company Overview
      • 6.4.3.2. Service Portfolio
      • 6.4.3.3. Recent Developments and Future Outlook
    • 6.4.4. Syngene
      • 6.4.4.1. Company Overview
      • 6.4.4.2. Financial Information
      • 6.4.4.3. Service Portfolio
      • 6.4.4.4. Recent Developments and Future Outlook

7. SURFACE GLYCAN TARGETING THERAPEUTICS: OVERALL MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Surface Glycan Targeting Therapeutics: Pipeline Review
    • 7.2.1. Analysis by Phase of Development
    • 7.2.2. Analysis by Target Disease Indication and Therapeutic Area
    • 7.2.3. Analysis by Type of Drug Molecule
    • 7.2.4. Analysis by Phase of Development and Therapeutic Area
    • 7.2.5. Analysis by Type of Drug Molecule and Therapeutic Area
    • 7.2.6. Analysis by Target Glycoconjugate and Glycan Molecule
    • 7.2.7. Analysis by Type of Therapy
    • 7.2.8. Popular Technology Platforms: Distribution by Number of Products
  • 7.3. Surface Glycan Targeting Therapeutics: List of Developers
    • 7.3.1. Analysis by Type of Player
    • 7.3.2. Analysis by Year of Establishment
    • 7.3.3. Analysis by Company Size
    • 7.3.4. Analysis by Location of Headquarters
    • 7.3.5. Leading Players: Analysis by Number of Products
  • 7.4. Heat Map Analysis: Distribution by Company Size, Location of Headquarters and Product's Stage of Development

8. SURFACE GLYCAN TARGETING THERAPEUTICS: ACADEMIC GRANTS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Surface Glycan Targeting Therapeutics: Academic Grants Analysis
    • 8.3.1. Analysis by Year of Grant Award
    • 8.3.2. Analysis by Amount Awarded
    • 8.3.3. Analysis by Administering Institute Center
    • 8.3.4. Analysis by Support Period
    • 8.3.5. Analysis by Administering Institute Center and Support Period
    • 8.3.6. Analysis by Type of Grant Application
    • 8.3.7. Analysis by Purpose of Grant Award
    • 8.3.8. Analysis by Activity Code
    • 8.3.9. Word Cloud Analysis: Emerging Focus Areas
    • 8.3.10. Analysis by Study Section Involved
    • 8.3.11. Popular NIH Departments: Analysis by Number of Grants
    • 8.3.12. Analysis by Type of Recipient Organization
    • 8.3.13. Prominent Program Officers: Analysis by Number of Grants
    • 8.3.14. Popular Recipient Organizations: Analysis by Number of Grants
    • 8.3.15. Regional Distribution of Recipient Organizations

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. List of Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year of Partnership and Type of Partner
    • 9.3.4. Analysis by Type of Partnership and Type of Partner
    • 9.3.5. Analysis by Year of Partnership and Type of Parent Company
    • 9.3.6. Analysis by Type of Partnership and Type of Parent Company
    • 9.3.7. Most Active Players: Analysis by Number of Partnerships
    • 9.3.8. Regional Analysis
    • 9.3.9. Intercontinental and Intracontinental Agreements
    • 9.3.10. Analysis by Therapeutic Area

10. MERGERS AND ACQUISITONS

  • 10.1. Chapter Overview
  • 10.2. Merger and Acquisition Models
  • 10.3. List of Mergers and Acquisitions
    • 10.3.1. Analysis by Type of Deal
    • 10.3.2. Analysis by Year of Deal
    • 10.3.3. Analysis by Geography
    • 10.3.4. Intercontinental and Intracontinental Deals
    • 10.3.5. Analysis by Company Size
    • 10.3.6. Ownership Change Matrix
    • 10.3.7. Key Players: Analysis by Number of Mergers and Acquisitions
    • 10.3.8. Analysis by Key Value Drivers

11. CASE STUDY ON POTENTIAL CLIENTS OF GLYCAN ANALYSIS SERVICE PROVIDERS

  • 11.1. Chapter Overview
  • 11.2. List of Fc Glycoengineered Antibody Developers
    • 11.2.1. Analysis by Year of Establishment
    • 11.2.2. Analysis by Company Size
    • 11.2.3. Analysis by Location of Headquarters
    • 11.2.4. Leading Players: Analysis by Number of Products
  • 11.3. Fc Glycoengineered Antibody Therapeutics: Pipeline Review
    • 11.3.1. Analysis by Phase of Development
    • 11.3.2. Analysis by Target Disease Indication
    • 11.3.3. Analysis by Therapeutic Area
    • 11.3.4. Analysis by Type of Antibody
    • 11.3.5. Analysis by Type of Biological Target
    • 11.3.6. Analysis by Type of Therapy
    • 11.3.7. Analysis by Route of Administration
    • 11.3.8. Analysis by Impact of Fc Engineering
    • 11.3.9. Analysis by Technology Platform Used

12. GLYCAN ANALYSIS SERVICES: MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Forecast Methodology and Key Assumptions
  • 12.3. Global Glycan Analysis Services Market, 2021-2030
  • 12.4. Global Glycan Analysis Services Market, 2021-2030: Distribution by Company Size
    • 12.4.1. Glycan Analysis Services Market for Small Companies, 2021-2030
    • 12.4.2. Glycan Analysis Services Market for Mid-sized Companies, 2021-2030
    • 12.4.3. Glycan Analysis Services Market for Large Companies, 2021-2030
  • 12.5. Global Glycan Analysis Services Market, Distribution by Type of Analytical Technique, 2021-2030
    • 12.5.1. Glycan Analysis Services Market for Spectroscopy-based Techniques, 2021-2030
    • 12.5.2. Glycan Analysis Services Market for Chromatography-based Techniques, 2021-2030
    • 12.5.3. Glycan Analysis Services Market for Microarray-based Techniques, 2021-2030
    • 12.5.4. Glycan Analysis Services Market for Electrophoresis-based Techniques, 2021-2030
  • 12.6. Global Glycan Analysis Services Market, 2021-2030: Distribution by Geography
    • 12.6.1 Glycan Analysis Services Market in the US, 2021-2030
    • 12.6.2 Glycan Analysis Services Market in Canada, 2021-2030
    • 12.6.3 Glycan Analysis Services Market in the UK, 2021-2030
    • 12.6.4 Glycan Analysis Services Market in France, 2021-2030
    • 12.6.5 Glycan Analysis Services Market in Germany, 2021-2030
    • 12.6.6 Glycan Analysis Services Market in Spain, 2021-2030
    • 12.6.7 Glycan Analysis Services Market in Italy, 2021-2030
    • 12.6.8 Glycan Analysis Services Market in Rest of Europe, 2021-2030
    • 12.6.9 Glycan Analysis Services Market in China, 2021-2030
    • 12.6.10 Glycan Analysis Services Market in Japan, 2021-2030
    • 12.6.11 Glycan Analysis Services Market in India, 2021-2030
    • 12.6.12 Glycan Analysis Services Market in Asia-Pacific and rest of the world, 2021-2030

13. EXECUTIVE INSIGHTS

  • 13.1. Chapter Overview
  • 13.2. GlycoAnalytics Core, University of California
    • 13.2.1. Company / Organization Overview
    • 13.2.2. Interview Transcript: Biswa Choudhury, Technical Director
  • 13.2. glyXera
    • 13.2.1. Company / Organization Overview
    • 13.2.2. Interview Transcript: Erdmann Rapp, Founder and Chief Executive Officer
  • 13.3. Glykos Finland
    • 13.3.1. Company / Organization Overview
    • 13.3.2. Interview Transcript: Juhani Saarinen, Chief Executive Officer

14. CONCLUDING REMARKS

  • 14.1. Chapter Overview

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Immunoregulatory Roles of Antibody Glycosylation
  • Figure 3.2 Methods used in Glycan Analysis
  • Figure 3.3 Risks Associated with Outsourcing Glycan Analysis
  • Figure 3.4 Guidelines for Selecting a Glycan Analysis Service Provider
  • Figure 4.1 Glycan Analysis Service Providers: Overall Market Landscape
  • Figure 4.2 Glycan Analysis Service Providers (Industry Players): Distribution by Year of Establishment
  • Figure 4.3 Glycan Analysis Service Providers (Industry Players): Distribution by Company Size
  • Figure 4.4 Glycan Analysis Service Providers (Industry Players): Distribution by Location of Headquarters
  • Figure 4.5 World Map Representation: Analysis by Geography
  • Figure 4.6 Glycan Analysis Service Providers (Industry Players): Distribution by Availability of Contract Development and Manufacturing Capabilities
  • Figure 4.7 Glycan Analysis Service Providers (Industry Players): Distribution by Types of Services Offered
  • Figure 4.8 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Glycoconjugate(s) / Glycan(s) Analyzed
  • Figure 4.9 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Sample(s) Processed
  • Figure 4.10 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Analyte(s) Processed
  • Figure 4.11 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Analytical Technique(s) Used
  • Figure 4.12 Glycan Analysis Service Providers (Industry Players): Distribution by Application Area(s)
  • Figure 4.13 Glycan Analysis Service Providers (Industry Players): Distribution by Additional Services Offered
  • Figure 4.14 Glycan Analysis Service Providers (Industry Players): Distribution by Additional Products Offered
  • Figure 4.15 Glycan Analysis Service Providers (Non-Industry Players): Distribution by Service Location
  • Figure 4.16 Glycan Analysis Service Providers (Non-Industry Players): Distribution by Type of Service(s) Offered
  • Figure 4.17 Glycan Analysis Service Providers (Non-Industry Players): Distribution by Type of Analytical Technique(s) Used
  • Figure 5.1 Competitiveness Analysis: Glycan Analysis Service Providers in North America
  • Figure 5.2 Competitiveness Analysis: Glycan Analysis Service Providers in Europe
  • Figure 5.3 Competitiveness Analysis: Glycan Analysis Service Providers in Asia-Pacific and rest of the world
  • Figure 5.4 Competitiveness Analysis of Glycan Analysis Service Providers: Competitiveness Score of Top Service Providers
  • Figure 6.1 Thermo Fisher Scientific: Annual Revenues, FY 2016-Q1 2021 (USD Billion)
  • Figure 6.2 Syngene: Annual Revenues, FY 2016-FY 2021 (INR Million)
  • Figure 7.1 Surface Glycan Targeting Therapeutics: Distribution by Phase of Development
  • Figure 7.2 Surface Glycan Targeting Therapeutics: Distribution by Target Disease Indication and Therapeutic Area
  • Figure 7.3 Surface Glycan Targeting Therapeutics: Distribution by Type of Drug Molecule
  • Figure 7.4 Surface Glycan Targeting Therapeutics: Distribution by Phase of Development and Therapeutic Area
  • Figure 7.5 Surface Glycan Targeting Therapeutics: Distribution by Type of Drug Molecule and Therapeutic Area
  • Figure 7.6 Surface Glycan Targeting Therapeutics: Distribution by Target Glycoconjugate and Glycan Molecule
  • Figure 7.7 Surface Glycan Targeting Therapeutics: Distribution by Type of Therapy
  • Figure 7.8 Popular Technology Platforms: Distribution by Number of Products
  • Figure 7.9 Surface Glycan Targeting Therapy Developers: Distribution by Type of Player
  • Figure 7.10 Surface Glycan Targeting Therapy Developers: Distribution by Year of Establishment
  • Figure 7.11 Surface Glycan Targeting Therapy Developers: Distribution by Company Size
  • Figure 7.12 Surface Glycan Targeting Therapy Developers: Distribution by Location of Headquarters
  • Figure 7.13 World Map Representation: Analysis by Geography
  • Figure 7.14 Leading Players: Distribution by Number of Products
  • Figure 7.15 Heat Map Analysis: Distribution by Company Size, Location of Headquarters and Products' Stage of Development
  • Figure 8.1 Grant Analysis: Cumulative Trend by Year of Grant Award, 2016-2021 (till March)
  • Figure 8.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), 2016-2021 (till March)
  • Figure 8.3 Grant Analysis: Distribution by Administering Institute Center
  • Figure 8.4 Grant Analysis: Distribution by Support Period
  • Figure 8.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
  • Figure 8.6 Grant Analysis: Distribution by Type of Grant Application
  • Figure 8.7 Grant Analysis: Distribution by Purpose of Grant Award
  • Figure 8.8 Grant Analysis: Distribution by Activity Code
  • Figure 8.9 Word Cloud: Emerging Focus Areas
  • Figure 8.10 Grant Analysis: Distribution by Study Section Involved
  • Figure 8.11 Popular NIH Departments: Distribution by Number of Grants
  • Figure 8.12 Grant Analysis: Distribution by Type of Recipient Organization
  • Figure 8.13 Most Prominent Program Officers: Distribution by Number of Grants
  • Figure 8.14 Popular Recipient Organizations: Distribution by Number of Grants
  • Figure 8.15 Grant Analysis: Regional Distribution of Recipient Organization
  • Figure 9.1 Partnerships and Collaborations: Cumulative Trend by Year of Partnership, 2015-2021 (till March)
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2021 (till March)
  • Figure 9.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 9.5 Most Active Players: Distribution by Number of Partnerships
  • Figure 9.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Parent Company
  • Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Parent Company
  • Figure 9.8 Most Active Players: Distribution by Number of Partnerships
  • Figure 9.9 Partnerships and Collaborations: Regional Distribution
  • Figure 9.10 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 9.11 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 10.1 Mergers and Acquisitions: Distribution by Type of Deal
  • Figure 10.2 Mergers and Acquisitions: Cumulative Year-Wise Distribution, 2015- 2021 (till March)
  • Figure 10.3 Mergers and Acquisitions: Distribution by Geography
  • Figure 10.4 Mergers and Acquisitions: Intercontinental and Intracontinental Distribution
  • Figure 10.5 Mergers and Acquisitions: Company Logo Landscape
  • Figure 10.6 Acquisitions: Distribution by Company Size
  • Figure 10.7 Acquisitions: Ownership Change Matrix
  • Figure 10.8 Mergers and Acquisitions: Key Players
  • Figure 10.9 Mergers and Acquisitions: Key Value Drivers
  • Figure 11.1 Fc Glycoengineered Antibody Developers: Distribution by Year of Establishment
  • Figure 11.2 Fc Glycoengineered Antibody Developers: Distribution by Company Size
  • Figure 11.3 Fc Glycoengineered Antibody Developers: Distribution by Location of Headquarters
  • Figure 11.4 Leading Players: Distribution by Number of Products
  • Figure 11.5 Fc Glycoengineered Antibodies: Distribution by Phase of Development
  • Figure 11.6 Fc Glycoengineered Antibodies: Distribution by Target Disease Indication
  • Figure 11.7 Fc Glycoengineered Antibodies: Distribution by Therapeutic Area
  • Figure 11.8 Fc Glycoengineered Antibodies: Distribution by Type of Antibody
  • Figure 11.9 Fc Glycoengineered Antibodies: Distribution by Type of Biological Target
  • Figure 11.10 Fc Glycoengineered Antibodies: Distribution by Type of Therapy
  • Figure 11.11 Fc Glycoengineered Antibodies: Distribution by Route of Administration
  • Figure 11.12 Fc Glycoengineered Antibodies: Distribution by Impact of Fc Engineering
  • Figure 11.13 Fc Glycoengineered Antibodies: Distribution by Technology Platform Used
  • Figure 12.1 Global Glycan Analysis Services Market, 2021-2030 (USD Million)
  • Figure 12.2 Global Glycan Analysis Services Market: Distribution by Company Size, 2021 and 2030: Base Scenario (USD Million)
  • Figure 12.3 Glycan Analysis Services Market for Small Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.4 Glycan Analysis Services Market for Mid-sized Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.5 Glycan Analysis Services Market for Large Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.6 Global Glycan Analysis Services Market: Distribution by Type of Analytical Technique (USD Million), 2021 and 2030
  • Figure 12.7 Glycan Analysis Services Market for Spectroscopy-based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.8 Glycan Analysis Services Market for Chromatography-based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.9 Glycan Analysis Services Market for Microarray- based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.10 Glycan Analysis Market for Electrophoresis- based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.11 Global Glycan Analysis Services Market: Distribution by Geography (USD Million), 2021 and 2030
  • Figure 12.12 Glycan Analysis Services Market in the US, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.13 Glycan Analysis Services Market in Canada, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.14 Glycan Analysis Services Market in the UK, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.15 Glycan Analysis Services Market in France, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.16 Glycan Analysis Services Market in the Germany, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.17 Glycan Analysis Services Market in Spain, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.18 Glycan Analysis Services Market in Italy, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.19 Glycan Analysis Services Market in Rest of Europe, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.20 Glycan Analysis Services Market in China, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.21 Glycan Analysis Services Market in Japan, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.22 Glycan Analysis Services Market in India, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.23 Glycan Analysis Services Market in Other Asian Countries and Rest of the World, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 14.1 Concluding Remarks: Overall Market Landscape of Glycosylation Analysis Service Providers
  • Figure 14.2 Concluding Remarks: Overall Market Landscape of Surface Glycan Targeting Therapeutics and Therapy Developers
  • Figure 14.3 Concluding Remarks: Academic Grants Analysis
  • Figure 14.4 Concluding Remarks: Partnerships and Collaborations
  • Figure 14.5 Concluding Remarks: Mergers and Acquisitions
  • Figure 14.6 Concluding Remarks: Market Sizing and Opportunity Analysis